Triamcinolone not checked

Research Insight LLC

FollowEvery change as it happens, and a Monday email
Next date
Phase 4 trial completes
Trials
2 active
2 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“triamcinolone 40mg/ml or topical clobetasol 0.05% with nepafenac 0.3% QD for 14 days”In the company’s words, NCT07276802 on ClinicalTrials.gov
Tested for
Post Cataract Surgery
Main trialPhase 4
“A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.”In the company’s words, NCT07276802 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting 31 Dec 2026 The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)
Phase 4Authorised not given Frozen shoulder – the role of physiotherapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Triamcinolone

Following is part of Solo: you see every change to Triamcinolone the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in